Who are Interferon alfa 2a [Roferon]'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Intron A, Peginterferon alfa 2, Peg-IFN α-2b combined with NAs, Placebo and peginterferon, Infergen and ribavirin, PegIFN alfa-2a.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/interferon-alfa-2a-roferon.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Interferon alfa 2a [Roferon] — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Interferon alfa 2a [Roferon] (Interferon alfa 2a [Roferon]) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interferon alpha. Area: Oncology, Immunology, Virology.

phase 3 Interferon alpha Interferon-alpha receptor (IFNAR1/IFNAR2) Oncology, Immunology, Virology Small molecule Live · refreshed every 30 min

Target snapshot

Interferon alfa 2a [Roferon] (Interferon alfa 2a [Roferon]) — Hoffmann-La Roche. Interferon alfa-2a activates the immune system by binding to interferon-alpha receptors on cell surfaces, enhancing natural killer cell and macrophage activity to fight viral infections and cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Interferon alfa 2a [Roferon] TARGET	Interferon alfa 2a [Roferon]	Hoffmann-La Roche	phase 3	Interferon alpha	Interferon-alpha receptor (IFNAR1/IFNAR2)
Intron A	INTERFERON ALFA-2B	Merck & Co.	marketed	Interferon alpha		1986-01-01
Peginterferon alfa 2	Peginterferon alfa 2	Dr. Conrado Fernandez	marketed	Interferon alpha	Interferon-alpha receptor (IFNAR)
Peg-IFN α-2b combined with NAs	Peg-IFN α-2b combined with NAs	Shenzhen Third People's Hospital	marketed	Interferon alpha combined with nucleos(t)ide reverse transcriptase inhibitor	Interferon-alpha receptor (IFNAR); HBV reverse transcriptase
Placebo and peginterferon	Placebo and peginterferon	National Taiwan University Hospital	marketed	Interferon alpha (pegylated)	Interferon-alpha receptor (IFNAR)
Infergen and ribavirin	Infergen and ribavirin	Kadmon Corporation, LLC	marketed	Interferon alpha and nucleoside analog combination	Interferon-alpha receptor (IFNAR); viral RNA-dependent RNA polymerase
PegIFN alfa-2a	PegIFN alfa-2a	The Second Affiliated Hospital of Chongqing Medical University	marketed	Pegylated interferon alpha	Interferon-alpha receptor (IFNAR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interferon alpha class)

Dr. Conrado Fernandez · 2 drugs in this class
Ain Shams University · 1 drug in this class
Beijing 302 Hospital · 1 drug in this class
Foundation for Liver Research · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Kexing Biopharm Co., Ltd. · 1 drug in this class
Merck & Co. · 1 drug in this class
ANRS, Emerging Infectious Diseases · 1 drug in this class
Vertex Pharmaceuticals Incorporated · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Interferon alfa 2a [Roferon] — Competitive Intelligence Brief. https://druglandscape.com/ci/interferon-alfa-2a-roferon. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing